GPRC5D-Specific CAR-T Cells for B Cell Malignancy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant unmet need for novel CAR-T cells designed to treat B cell malignancies, including multiple myeloma, as many patients do not respond to current CAR-T therapies or develop humoral immunity against them, and existing manufacturing methods face challenges in availability and access.
Innovation Solution
The development of isolated polypeptides, antibodies, and chimeric antigen receptors (CARs) that specifically bind to G protein-coupled receptor class C group 5 member D (GPRC5D), along with fusion proteins and viral vectors, to enhance the targeting and efficacy of CAR-T cells in treating B cell malignancies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current CAR-T therapies are used to treat B cell malignancies, then some patients achieve treatment response, but many patients do not respond or develop humoral immunity against the therapy
Solution Approach 1:
The patent applies parameter changes by modifying the CAR construct parameters - specifically using a novel GPRC5D-specific antibody variable region (Seq ID Nos: 1-3) with optimized amino acid sequences to alter the binding affinity and specificity parameters, thereby improving treatment response while reducing immunogenicity compared to conventional CAR-T therapies
2Productivity
If CAR-T cells are manufactured using existing methods, then CAR-T cells can be produced, but manufacturing availability and access face significant challenges
Solution Approach 1:
The patent employs disposable viral vector systems for CAR delivery that can be produced and distributed more easily than complex manufacturing processes, improving accessibility. The use of standardized vector backbones and modular CAR constructs enables simplified manufacturing that can be performed at multiple facilities, thereby enhancing productivity and ease of manufacture
3Reliability
If GPRC5D-specific antibody variable regions are used in CAR constructs, then cytolytic activity and tumor control are enhanced, but the complexity of the therapeutic construct increases
Solution Approach 1:
The patent extracts only the essential antigen-binding variable regions (VH and VL) from the complete antibody structure to create the CAR construct. This extraction approach maintains the critical tumor-targeting function while eliminating unnecessary portions of the antibody, thereby enhancing tumor control efficacy while managing construct complexity
Data Source
AI summary
Disclosed herein are antibodies or antigen binding fragments that specifically bind human GPRC5D. Also disclosed are chimeric antigen receptors and chimeric antigen receptor transgenes comprising an antigen binding domain that specifically binds human GPRC5D and fusion proteins comprising a Henipavirus glycoprotein G and a GPRC5D antibody, or an antigen binding fragment thereof. Viral vectors and other compositions containing the antibodies or antigen binding fragments thereof, chimeric antigen receptors and chimeric antigen receptor transgenes, and fusion proteins are disclosed. The present disclosure additionally relates to cells expressing chimeric antigen receptors, as well as methods of delivering the various antibodies and chimeric antigen receptors and methods of using cells expressing the chimeric antigen receptors.